Earnings Releases·Nov 4, 2026, 4:07 PM ET

Myriad Genetics — Third Quarter 2026 Earnings Summary

Full-year 2026 revenue guidance raised to $780–$790 million (mid-point), while Q3 revenue fell 1% year-over-year to $202.7 million; net loss widened to $43.9 million ($0.46/share) from $27.4 million in the prior year period.
Announced definitive agreement to sell Prenatal Health business to Labcorp for $210 million in cash plus inventory value, expected to close by early 2027, with full-year Prenatal revenue guidance set at approximately $160 million.
Core segments (Cancer Care Continuum and Mental Health) drove sequential growth with combined revenue up 1% year-over-year to $163.4 million and test volume up 3%, though gross margin contracted 200 basis points to 67.9%.
Strategic initiatives include advancing MRD testing via new MONSTAR-SCREEN-3 data, securing Medicare coverage for Precise MRD, and a new collaboration with SOPHiA GENETICS and AstraZeneca for prostate cancer genomic instability technology.